The LAT CAB was created in 2021 to ensure community engagement with researchers working on the development of long-acting technologies under the Unitaid-funded Longevity project. It consists of 12 members from 11 low- and middle-income countries with excellent knowledge based on technical skills, activism experience, engagement with civil society networks, and quality of application materials. The LAT CAB is co-coordinated by TAG and Afrocab Treatment Access Partnership, and the members are people with lived experiences with malaria, tuberculosis, and hepatitis C virus (HCV) with strong civil society and policy experiences who may benefit from the development of long-acting medicines. Through this International AIDS Society Conference video, LAT CAB members describe the goal of the CAB, how long-acting therapies for malaria and latent TB prevention and HCV cure will benefit affected communities, and what they have gained from their LAT CAB membership.
This video, offered here in English, French, and Spanish, was made to be shown at the AfroCAB booth at the 24th International AIDS Conference.